Eleven Therapeutics
Focus: Eleven Therapeutics is an Israeli biotech specializing in small interfering RNAs (siRNAs) with ultra-long durability using high-throughput combinatorial chemistry and AI. The company operates at pre-revenue stage with a diversified pipeline spanning ophthalmology, oncology, and neurodegenerative diseases.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Total Funding
$20M
Open Jobs
0
About Eleven Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Eleven Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
EBI-031
Diabetic Macular EdemaClinical Trials (1)
NCT02842541Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema
Phase 1Help build intelligence for Eleven Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.